Product Description
PCR Markets: Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets with Executive and Consultant Guides, Including Customized Forecasting and Analysis. Updated to include impact of COVID-19 Diagnostics 2022 to 2026
“COVID-19 drives PCR market expansion but what next? New multiplex markets see accelerated development outlook...”
COVID-19 Diagnostics is driving PCR into a dominant technology role and spurring the growth of new PCR based technologies.
- Will thermal cycling become obsolete?
- Will singleplex tests become a thing of the past?
- Will routine cancer screening become a reality?
- Will diagnostics move into the Physician’s Office or the home?
- Will digital PCR become the new lab standard?
The report forecasts the market size out to 2026 with the only analysis available that breaks out Singleplex and Multiplex testing markets. PCR has proved itself in the market and the new generation of PCR, digital PCR promises to keep that success going, driven even faster by the huge demand for pandemic diagnostics. New levels of sensitivity have implications for Liquid Biopsy and Cancer Screening markets. Lowering costs, improving outcomes and even helping in the battle against antimicrobial resistance (AMR). Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success.
Subscribe and Save
By signing up for the annual subscription, updates to this report will be automatically provided free of charge for a period of one year from initial purchase. These updates can include revised forecasts as markets increase or contract and exclusive market commentary not seen anywhere else. With the effects of COVID-19 being felt across all markets it has never been more crucial to stay fully informed with real-world actionable data. Subscribe to this report and receive ongoing market forecasting and analysis for sharpened strategic planning throughout the year.
Subscription deliverables:
- Quarterly report updates
- Summary of significant developments and market changes
- Phone consultation and assistance on request for the duration of the subscription
All report data is available in Excel format on request with the corporate license.
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options, however your order is available as a credit if you wish to upgrade. We wrote this report and are ready by phone or email to help you use it.
Assistance and additional breakout data is available free of charge with the corporate license.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School
